Jim Cramer has been circling the wagons back to Bristol-Myers, and says it is too attractive to ignore right now.
CNBC's Meg Tirrell reports the latest on the response from EpiPen maker Mylan to Sen. Chuck Grassley's inquiries over the controversial price hike for the drug.
A study claims benefits of the cholesterol-reducing drug are underestimated while risks have been exaggerated.
Allergan CEO Brent Saunders speaks to CNBC's Meg Tirrell about his promise for responsible drug prices, Clinton's drug proposal, Valeant and Mylan's EpiPen price hike.
David Maris, Wells Fargo Securities, and CNBC's Meg Tirrell talk about rebates, the outrage over drug prices and Hillary Clinton's drug price plan.
Sept 8- Drugstore chain Walgreens Boots Alliance Inc said it would likely have to divest between 500 and 1000 stores, more than its previous estimate, to win regulatory approval for its planned acquisition of Rite Aid Corp.. Rite Aid shares were up 6.5 percent at $8.28 in early trading on Thursday. Walgreens, in October last year, offered to buy smaller peer Rite Aid...
Sept 8- Drugstore chain Walgreens Boots Alliance Inc said it would likely have to divest between 500 and 1000 stores to win regulatory approval for its planned acquisition of Rite Aid Corp.. Walgreens had earlier estimated it would not have to sell more than 500 stores to win over regulators. The company offered to buy smaller peer Rite Aid in October last year to...
Valeant CEO Joseph Papa discusses his plans for turning around the company, and whether the company will sell off assets.
Valeant CEO Joseph Papa discusses his plans for turning around the company, whether the company will sell off assets, drug prices, Pershing Square's Bill Ackman and lawsuits.
Toby Cosgrove, Cleveland Clinic, discusses Clinton's drug price plan and the controversy surrounding drug price hikes.
CNBC's Meg Tirrell reports on the Clinton Campaign's plan to combat high drug prices.
Mylan shares were hit again after Senator Amy Klobuchar released a report saying Mylan may have misclassified EpiPen under Medicaid. Senator Klobuchar explains.
CNBC's Meg Tirrell reports the latest on Hillary Clinton's plan to curb drug price hikes and how the pharma industry could react.
Scott Stringer, (D) NYC Comptroller, discusses the city's letter to the board of Mylan over the risks of EpiPen price hikes for New York City's pension funds.
The Democratic presidential candidate would create a consumer response team to monitor drug price hikes.
CNBC's John Harwood reports Hillary Clinton's new plan to tackle drug price hikes.
Fred Hassan, Warburg Pincus Partner & Managing Director, discusses the issue of drug pricing for consumers in the wake of the Mylan EpiPen pricing saga.
CNBC's Meg Tirrell speaks to former Teva CEO Jeremy Levin about drug-price hikes, and why he thinks the pharmaceutical system is in need of change.
Dr. Ezekiel Emanuel, University of Pennsylvania Chair of Medical Ethics & Health Policy, weighs in on the drug pricing debate in the wake of Mylan's EpiPen pricing saga.
CNBC's Meg Tirrell reports the latest on Mylan following the announcement that it will release a generic version of its EpiPen.